Frontlight ResearchEarly access
Sarcoma trials in South Korea
15 of 17 trials · From ClinicalTrials.gov, checked 14 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Where
- Bupyeong-gu, Daegu, Hwasun, Incheon, Junggu, Seoul, Suwon, Yangsan
- Age
- 18 years and over
- People
- 348 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00 - Phase 2Taking peopleKEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
- Where
- Seoul
- Age
- 18 years and over
- People
- 140 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07252739 · EU 2025-521939-36-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- Where
- Busan, Daegu, Daejeon, Gyeonggi-do, Incheon, Jeollanam-do, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07541170 · EU 2025-524263-21-01 - Phase 3Taking peopleImpact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
- Where
- Incheon, Seoul
- Age
- 18 years and over
- People
- 428 worldwide
- Run by
- NRG Oncology
See details and how to joinNCT05646316 - Phase 2Taking peopleA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Jongno -Gu, Seoul
- Age
- 18 years and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00 - Phase 1/2Taking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Seoul
- Age
- 6 months to 25 years
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00 - Phase 1/2Taking peopleStudy to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
- Where
- Gyeonggi-do, Seoul
- Age
- 12 years and over
- People
- 78 worldwide
- Run by
- MedPacto, Inc.
See details and how to joinNCT05588648 - Phase 1/2Taking peopleA Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Where
- Seoul
- Age
- Up to 25 years
- People
- 75 worldwide
- Run by
- Turning Point Therapeutics, Inc.
See details and how to joinNCT04094610 · EU 2023-506464-14-00 - Phase 1Taking peopleFirst-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
- Where
- Seoul
- Age
- 18 years and over
- People
- 150 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06644755 - Phase 1/2Taking peopleA Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Where
- Cheongju-si, Hwasun-eup, Hwasun-gun, Seoul
- Age
- 12 years and over
- People
- 500 worldwide
- Run by
- Turning Point Therapeutics, Inc.
See details and how to joinNCT03093116 · EU 2024-512606-25-00 - Phase 2Taking peoplePemetrexed, Cisplatin With Soft Tissue Sarcoma
- Where
- Seoul
- Age
- 19 years and over
- People
- 164
- Run by
- Yonsei University
See details and how to joinNCT04605770 - No phaseNot yet taking people in South KoreaProspective Phase I/II Study Evaluating the Safety and Efficacy of Preoperative Carbon Ion Radiotherapy in Patients With Soft Tissue Sarcoma : The SARCOMA-01 Trial by the Severance sARCOma Multidisciplinary Team
- Where
- Seoul
- Age
- 19 years and over
- People
- 60
- Run by
- Yonsei University
See details and how to joinNCT07250334 - Phase 2Taking peoplePazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma
- Where
- Seoul
- Age
- 20 years to 80 years
- People
- 116
- Run by
- Yonsei University
See details and how to joinNCT05679921 - Phase 1/2Taking peopleA Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- Where
- Seoul, Suwon
- Age
- 18 years and over
- People
- 358 worldwide
- Run by
- GI Innovation, Inc.
See details and how to joinNCT05824975 - Phase 1/2Not yet taking people in South KoreaA Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
- Where
- Donggu
- Age
- 2 years to 25 years
- People
- 148 worldwide
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT05590572